BioDelivery Sciences International(NASDAQ:BDSI) announced the earnings results for Fiscal Year 2016 and Q4. The results came in during Pre-Market on Mar 17, 2017. Based on the corporate Earnings and Guidance, many Investment Banking firms balance their portfolio to Sell and Buy Stocks based on their strategy of investing in stocks.Company reported revenue of $3.931M. Analysts estimated a revenue of $3.890M. The revenues were 1.05% above the estimates. Earnings per share were $-0.29. The reported EPS was below estimates by -11.54%. Analysts had estimated an EPS of $-0.26.
BioDelivery Sciences International (BDSI) made into the market gainers list on Wednesdays trading session with the shares advancing 1.32% or 0.025 points. Due to strong positive momentum, the stock ended at $1.925, which is also near the day’s high of $1.95. The stock began the session at $1.9 and the volume stood at 2,59,765 shares. The 52-week high of the shares is $4 and the 52 week low is $1.5. The company has a current market capitalization of $105 M and it has 5,47,96,622 shares in outstanding.
Several Insider Transactions has been reported to the SEC. On Mar 3, 2017, Niraj Vasisht (SVP & Chief Technology Officer) sold 42,000 shares at $2.00 per share price.Also, On Mar 3, 2017, Paolantonio Ernest Robert De (officer ) sold 19,750 shares at $2.00 per share price.On Feb 24, 2017, Francis E Jr Odonnell (director) sold 129,860 shares at $1.90 per share price, according to the Form-4 filing with the securities and exchange commission.
BioDelivery Sciences International Inc. is a specialty pharmaceutical company. The Company develops and commercializes either on its own or in partnerships with third parties applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction. The Company’s products and certain of its product candidates utilize the BioErodible MucoAdhesive (BEMA) drug delivery technology a small erodible polymer film for application to the buccal mucosa (the lining inside the cheek). The Company’s United Sates Food and Drug Administration (FDA) approved product ONSOLIS (fentanyl buccal soluble film) as well as its approved product BUNAVAIL (buprenorphine and naloxone buccal film) and its product candidate BELBUCA utilize its BEMA technology.